



ADVANCED BIOSCIENCE RESOURCES, INC.

## FEES FOR SERVICES SCHEDULE

Effective January 1, 2017

### FETAL CADAVEROUS SPECIMEN PROCUREMENT

### SERVICE FEE

2nd trimester specimen (13 - 24 weeks) .....PER SPECIMEN  
1st trimester specimen (8 - 12 weeks) .....PER SPECIMEN

(b) (4)

### BLOOD SPECIMEN PROCUREMENT

Maternal Peripheral .....PER SPECIMEN  
Adult Peripheral .....PER SPECIMEN  
Full Term Umbilical Cord .....PER SPECIMEN

### SPECIAL PROCESSING / PRESERVATION

Case Report Form (CRF) completion .....PER CASE  
Specimen "cleaning" .....PER SPECIMEN  
Special requests (evaluated individually) .....PER SPECIMEN  
Snap freezing (LN2) .....PER SPECIMEN  
Passive freezing (Dry ice) .....PER SHIPMENT  
Foreign shipments .....PER SHIPMENT  
Electronic Fund Transfer (EFT) (Fee varies by bank) .....PER INVOICE

(b) (4)

(b) (4)

(b) (4)

*The following fees are subject to change, based upon increases imposed from outside labs and courier companies.*

### INFECTIOUS DISEASE SCREENING (Testing performed on donor blood)

HIV, HBsAg .....  
Additional tests ..... CALL

(b) (4)

CALL

### DELIVERY (Research facility responsible for delivery charges.)

(FedEx billed on research facility's account but reversed to ABR will incur a \$15 rebill fee)

Federal Express Priority Overnight .....  
Federal Express First Overnight .....  
Federal Express Saturday Delivery .....  
Other courier services ..... CALL  
Fuel surcharge (Research facility responsible for additional fuel surcharge)..... CALL

\$(b) (4)

\$

\$

CALL

CALL

**Our Terms: Full payment due upon invoice receipt, and within 30 days of the invoice date.  
Accounts not paid within 30 days of invoice are subject to a 1.5% monthly finance charge.**

**From:** (b) (6), (b) (6)  
**To:** (b) (6), (b) (6)  
**Cc:** (b) (6), (b) (6); [Perrin Venosta-Larton](#); [Perrin Larton](#)  
**Subject:** Re: FW: FDA RFQ - 620 FDA-Howard Revision #2 - Quote #1762001-QT  
**Date:** Tuesday, July 18, 2017 12:25:45 PM  
**Attachments:** [image001.png](#)  
[image002.png](#)  
[20170705 2017 Fee Schedule.pdf](#)

---

Hello (b) (6),

Having subsequently received the P.O., I thought this requirement had already been fulfilled and so a response was no longer necessary.

We do not have a website, and we don't allow 'the public' to request tissue. It is only sent to verified researchers who have applied and have been approved to receive tissue.

As we are not selling items, we do not have prices. We assess fees for our services. The only document provided then to qualified recipients would be our Fees For Services Schedule. I've attached another copy of our current Fee Schedule for your reference. We're a small non-profit company, and the fees are the same for everyone.

I hope this fulfills your requirement. We've done business with the F.D.A. for many years and we've not experienced such rigorous procedures for the production of purchase orders. Will this process be necessary for each P.O. created now?

(b) (6), (b) (6)  
(4)

On Tue, Jul 18, 2017 at 5:01 AM, (b) (6) <[@fda.hhs.gov](mailto:(b) (6)@fda.hhs.gov)> wrote:

Good morning,

Please see my message below. Thank you.

Best regards,

(b) (6)

Contract Specialist

OAGS, FDA

Phone: (b) (6)



The information supplied in this message and any of its attachments may be legally privileged or proprietary in nature. If you are not the intended recipient, the sender does not intend delivery to you to waive any privileges or rights pertaining to this message. If you have received this message in error, please immediately notify the sender by return e-mail, and delete the errant message. Thank you.

---

**From:** (b) (6)  
**Sent:** Friday, July 14, 2017 9:34 AM  
**To:** (b) (6), (b) (4)  
**C** errin Venosta-Larton; Perrin Larton  
**Su** : FDA RFQ - 620 FDA-Howard Revision #2 - Quote #1762001-QT

Good morning,

In order to properly document pricing, I require some documentation of your prices as offered to the public. Would you be able to provide either redacted invoices or direct me to a place on your website that lists prices? I really appreciate your assistance with this requirement. Thank you.

Best regards,

(b) (6)

Contract Specialist

OAGS, FDA

Phone: (b) (6)



The information supplied in this message and any of its attachments may be legally privileged or proprietary in nature. If you are not the intended recipient, the sender does not intend delivery to you to waive any privileges or rights pertaining to this message. If you have received this message in error, please immediately notify the sender by return e-mail, and delete the errant message.